147 related articles for article (PubMed ID: 14610416)
1. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
Nanus DM; Milowsky MI; Kostakoglu L; Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Bander NH
J Urol; 2003 Dec; 170(6 Pt 2):S84-8; discussion S88-9. PubMed ID: 14610416
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
[TBL] [Abstract][Full Text] [Related]
3. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
Milowsky MI; Nanus DM; Kostakoglu L; Sheehan CE; Vallabhajosula S; Goldsmith SJ; Ross JS; Bander NH
J Clin Oncol; 2007 Feb; 25(5):540-7. PubMed ID: 17290063
[TBL] [Abstract][Full Text] [Related]
4. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
[TBL] [Abstract][Full Text] [Related]
5. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ
Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Bander NH; Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ
J Clin Oncol; 2005 Jul; 23(21):4591-601. PubMed ID: 15837970
[TBL] [Abstract][Full Text] [Related]
8. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
Lu SX; Takach EJ; Solomon M; Zhu Q; Law SJ; Hsieh FY
J Pharm Sci; 2005 Apr; 94(4):788-97. PubMed ID: 15729708
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ; Bander NH
J Clin Oncol; 2004 Jul; 22(13):2522-31. PubMed ID: 15173215
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
Vallabhajosula S; Nikolopoulou A; Jhanwar YS; Kaur G; Tagawa ST; Nanus DM; Bander NH; Goldsmith SJ
Curr Radiopharm; 2016; 9(1):44-53. PubMed ID: 25771365
[TBL] [Abstract][Full Text] [Related]
11. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.
Tagawa ST; Beltran H; Vallabhajosula S; Goldsmith SJ; Osborne J; Matulich D; Petrillo K; Parmar S; Nanus DM; Bander NH
Cancer; 2010 Feb; 116(4 Suppl):1075-83. PubMed ID: 20127956
[TBL] [Abstract][Full Text] [Related]
12. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
Morris MJ; Divgi CR; Pandit-Taskar N; Batraki M; Warren N; Nacca A; Smith-Jones P; Schwartz L; Kelly WK; Slovin S; Solit D; Halpern J; Delacruz A; Curley T; Finn R; O'donoghue JA; Livingston P; Larson S; Scher HI
Clin Cancer Res; 2005 Oct; 11(20):7454-61. PubMed ID: 16243819
[TBL] [Abstract][Full Text] [Related]
13. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
Pandit-Taskar N; O'Donoghue JA; Beylergil V; Lyashchenko S; Ruan S; Solomon SB; Durack JC; Carrasquillo JA; Lefkowitz RA; Gonen M; Lewis JS; Holland JP; Cheal SM; Reuter VE; Osborne JR; Loda MF; Smith-Jones PM; Weber WA; Bander NH; Scher HI; Morris MJ; Larson SM
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2093-105. PubMed ID: 25143071
[TBL] [Abstract][Full Text] [Related]
14. Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting.
Mukherjee A; Kumar B; Hatano K; Russell LM; Trock BJ; Searson PC; Meeker AK; Pomper MG; Lupold SE
Mol Cancer Ther; 2016 Oct; 15(10):2541-2550. PubMed ID: 27486224
[TBL] [Abstract][Full Text] [Related]
15. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
[TBL] [Abstract][Full Text] [Related]
17. The utility of monoclonal antibodies in the imaging of prostate cancer.
Yao D; Trabulsi EJ; Kostakoglu L; Vallabhajosula S; Joyce MA; Nanus DM; Milowsky M; Liu H; Goldsmith SJ
Semin Urol Oncol; 2002 Aug; 20(3):211-8. PubMed ID: 12215974
[TBL] [Abstract][Full Text] [Related]
18. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
David KA; Milowsky MI; Kostakoglu L; Vallabhajosula S; Goldsmith SJ; Nanus DM; Bander NH
Clin Genitourin Cancer; 2006 Mar; 4(4):249-56. PubMed ID: 16729907
[TBL] [Abstract][Full Text] [Related]
20. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
